JPWO2020190483A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020190483A5 JPWO2020190483A5 JP2021555228A JP2021555228A JPWO2020190483A5 JP WO2020190483 A5 JPWO2020190483 A5 JP WO2020190483A5 JP 2021555228 A JP2021555228 A JP 2021555228A JP 2021555228 A JP2021555228 A JP 2021555228A JP WO2020190483 A5 JPWO2020190483 A5 JP WO2020190483A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric antigen
- cells
- antigen receptor
- amino acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 41
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 210000000822 natural killer cell Anatomy 0.000 claims description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 230000003834 intracellular effect Effects 0.000 claims description 18
- 210000002540 macrophage Anatomy 0.000 claims description 16
- 210000000440 neutrophil Anatomy 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 206010010144 Completed suicide Diseases 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 108010057085 cytokine receptors Proteins 0.000 claims description 4
- 102000003675 cytokine receptors Human genes 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004039 Caspase-9 Human genes 0.000 claims description 2
- 108090000566 Caspase-9 Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108010001515 Galectin 4 Proteins 0.000 claims description 2
- 102100039556 Galectin-4 Human genes 0.000 claims description 2
- 102000010956 Glypican Human genes 0.000 claims description 2
- 108050001154 Glypican Proteins 0.000 claims description 2
- 108050007237 Glypican-3 Proteins 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims description 2
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 2
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 2
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims description 2
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 201000000062 kidney sarcoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024194375A JP2025013530A (ja) | 2019-03-15 | 2024-11-06 | Ｃｄ１４７キメラ抗原受容体および使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819403P | 2019-03-15 | 2019-03-15 | |
| US62/819,403 | 2019-03-15 | ||
| PCT/US2020/020436 WO2020190483A1 (en) | 2019-03-15 | 2020-02-28 | Cd147 chimeric antigen receptors and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024194375A Division JP2025013530A (ja) | 2019-03-15 | 2024-11-06 | Ｃｄ１４７キメラ抗原受容体および使用の方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525318A JP2022525318A (ja) | 2022-05-12 |
| JP2022525318A5 JP2022525318A5 (https=) | 2023-02-24 |
| JPWO2020190483A5 true JPWO2020190483A5 (https=) | 2023-02-24 |
| JP7602803B2 JP7602803B2 (ja) | 2024-12-19 |
Family
ID=72520374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555228A Active JP7602803B2 (ja) | 2019-03-15 | 2020-02-28 | Ｃｄ１４７キメラ抗原受容体および使用の方法 |
| JP2024194375A Withdrawn JP2025013530A (ja) | 2019-03-15 | 2024-11-06 | Ｃｄ１４７キメラ抗原受容体および使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024194375A Withdrawn JP2025013530A (ja) | 2019-03-15 | 2024-11-06 | Ｃｄ１４７キメラ抗原受容体および使用の方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220152106A1 (https=) |
| EP (1) | EP3938402A4 (https=) |
| JP (2) | JP7602803B2 (https=) |
| CN (1) | CN113853390B (https=) |
| CA (1) | CA3132458A1 (https=) |
| WO (1) | WO2020190483A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021396332A1 (en) * | 2020-12-11 | 2023-06-22 | Purdue Research Foundation | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use |
| WO2022138282A1 (ja) * | 2020-12-22 | 2022-06-30 | 荒木技研工業株式会社 | 金属管の分岐部構造製造装置及び金属管の分岐部構造の製造方法 |
| WO2023147019A2 (en) * | 2022-01-28 | 2023-08-03 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| WO2024220483A2 (en) * | 2023-04-19 | 2024-10-24 | Rutgers, The State University Of New Jersey | Grp78 chimeric antigen receptors and combination therapies for treating cancer |
| WO2025105442A1 (ja) * | 2023-11-15 | 2025-05-22 | 大塚製薬株式会社 | キメラ抗原受容体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003828A1 (en) * | 1993-08-02 | 1995-02-09 | Houston Biotechnology Incorporated | Single-chain immunotoxin compositions and methods for preventing secondary cataracts |
| AU2009296937B2 (en) * | 2008-09-29 | 2015-02-12 | Centocor Ortho Biotech Inc. | Anti-CD147 antibodies, methods, and uses |
| ES2869972T3 (es) * | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| WO2016210447A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| WO2018165619A1 (en) * | 2017-03-09 | 2018-09-13 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
-
2020
- 2020-02-28 EP EP20773750.3A patent/EP3938402A4/en active Pending
- 2020-02-28 US US17/438,741 patent/US20220152106A1/en active Pending
- 2020-02-28 WO PCT/US2020/020436 patent/WO2020190483A1/en not_active Ceased
- 2020-02-28 JP JP2021555228A patent/JP7602803B2/ja active Active
- 2020-02-28 CA CA3132458A patent/CA3132458A1/en active Pending
- 2020-02-28 CN CN202080035700.8A patent/CN113853390B/zh active Active
-
2024
- 2024-11-06 JP JP2024194375A patent/JP2025013530A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108610420B (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| AU2018204209B2 (en) | Method and compositions for cellular immunotherapy | |
| JP2024023228A5 (https=) | ||
| JP2022191241A5 (https=) | ||
| JP7269167B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| CN110662771A (zh) | 一种结合bcma的嵌合抗原受体(car)及其应用 | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| JP2022516389A5 (https=) | ||
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| JP2020522473A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| JP2015513920A5 (https=) | ||
| JP2019513370A5 (https=) | ||
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2018526033A5 (https=) | ||
| CN109796532B (zh) | 靶向成纤维激活蛋白α的结合单元及其应用 | |
| JP2020501512A5 (https=) | ||
| KR20230022411A (ko) | 키메라 항원 수용체 스페이서 | |
| CA3068039A1 (en) | A target cell-dependent t cell engaging and activation asymmetric heterodimeric fc-scfv fusion antibody format for cancer therapy | |
| CA3233085A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| Sugiyama et al. | A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity | |
| WO2022224997A1 (ja) | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 | |
| JPWO2020190483A5 (https=) | ||
| WO2015172341A1 (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| JPWO2023034922A5 (https=) |